Kendall McFarland
Women's Health · Madison, ALNPI 1194360800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 68 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$218
- Daiichi Sankyo Inc.$216
- Bayer$109
- Organon$85
- Sage Therapeutics, LLC$64
- Exeltis, USA Inc.$63
- plus $453 from 15 others
What the payments were for
- Food & beverage$1,208100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $218 |
| Daiichi Sankyo Inc. | 11 | $216 |
| Bayer | 6 | $109 |
| Organon | 4 | $85 |
| Sage Therapeutics, LLC | 4 | $64 |
| Exeltis, USA Inc. | 4 | $63 |
| Novo Nordisk | 3 | $61 |
| Pfizer | 3 | $58 |
| Pacira Pharmaceuticals Incorporated | 2 | $46 |
| Davol Inc. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Shield Therapeutics Inc | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Scynexis, Inc. | 1 | $17 |
| Mylan Pharmaceuticals Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Merck | 1 | $15 |
| Vertex | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Minerva Surgical, Inc | 1 | $12 |
How this compares
$1,208 in reported general payments places this provider in the 70th percentile of 107 women's health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 11 | $2,807 |
| Estradiol | 21 | $1,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $58 | $2,80711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 107 women's health providers in Alabama.
Other women's health in Madison
- Bethel RenfrowMadison$2K
- Ashton TureaudBirmingham$26K
- Mary MatteiMobile$10K
- Kathryn LyleBirmingham$7K
- Tracy BrownFoley$6K
- Kimberly PeekHuntsville$6K
- Karen HammondHoover$6K
- Jessica MorrisonBirmingham$5K
- Dawna FranklinBirmingham$5K
- Mitzi ThompsonSpanish Fort$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.